Prognosis-related molecular markers in pediatric central nervous system tumors

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 12, 2004, Pages 1211-1224

  Rickert, Christian H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Childhood brain tumors; Molecular markers; Prognosis; Tumor therapy

Indexed keywords

CELL ADHESION MOLECULE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN P; GROWTH FACTOR; HORMONE RECEPTOR; METALLOTHIONEIN; MOLECULAR MARKER; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P27; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; TENASCIN; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

ASTROCYTOMA; BRAIN TUMOR; CANCER SURVIVAL; CELL CYCLE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; EPENDYMOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDULLOBLASTOMA; MULTIDRUG RESISTANCE; ONCOGENE C ERB; ONCOGENE C MYB; ONCOGENE C MYC; ONCOGENE NEU; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 10044228266     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.12.1211     Document Type: Review

References (81)

1. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45
2. Fuller GN, Hess KR, Rhee CH, et al. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 2002;12:108-16
3. Rickert CH, Sträter R, Kaatsch P, et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 2001;158:1525-32
4. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Eng J Med 2002;346:420-27
5. Pomeroy SL, Tamayo P, Gaasenbeek, M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42
6. Gushing N. Intracranial tumors: Notes upon a series of two thousand verified cases with surgical-mortality percentages pertaining thereto. Springfield, IL: Charles C. Thomas, 1932
7. Kaatsch P, Rickert CH, Kühl J, Schüz J, Michaelis J. Population-based epidemiological data of brain tumors in German children. Cancer 2001;92:3155-64
8. Ellison D. Classifying the medulloblastoma: Insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002;28:257-82
9. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7
10. Rickert CH, Paulus W. Comparative genomic hybridization in central and peripheral nervous system tumors of childhood and adolescence. J Neuropathol Exp Neurol 2004;63:399-417
11. Ben Arush MW, Linn S, Ben-Izhak O, et al. Prognostic significance of DNA ploidy in childhood astrocytomas. Pediatr Hematol Oncol 1999;16:387-96
12. Rostomily RC, Hoyt JW, Berger MS, et al. Pleomorphic xanthoastrocytoma. DNA flow cytometry and outcome analysis of 12 patients. Cancer 1997;80:2141-50
13. Munoz EL, Eberhard DA, Lopes MBS, Schneider BF. Gonzales F, VandenBerg SR. Proliferative activity and p53 mutation as prognostic indicators in pleomorphic xanthoustrocytoma. (Abstract) J Neuropathol Exp Neurol 1996;55:606
14. Paulus W, Lisle DK, Tonn JC, et al. Molecular genetic alterations in pleomorphic xanthoastrocytoma. Acta Neuropathol 1996;91:293-97
15. Drach LM, Kammermeier M, Neirich U, et al. Accumulation of nuclear p53 protein and prognosis of astrocytomas in childhood and adolescence. Clin Neuropathol 1996;15:67-73
16. Pollack IF, Campbell JW, Hamilton RL, Martinez AJ, Bozik ME. Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer 1997;79:849-56
17. Bredel M, Pollack IF, Hamilton RL, Birner P, Hainfellner JA, Zentner J. DNA topoisomerase IIalpha predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas. Int J Cancer 2002;99:817-20
18. Raffel C, Frederick L, O'Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999:5:4085-90
19. Van Meir EG. "Turcot's syndrome": Phenotype of brain tumors, survival and mode of inheritance. Int J Cancer 1998;75:162-64
20. Pollack IF, Finkelstein SD, Burnham J, et al. Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: Results from the CCG-945 cohort. Pediatr Neurosurg 2003;39:114-21
21. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol 1997;7:807-22
22. Korshunov A, Sycheva R, Timirgaz V, Golanov A. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: An analysis of 76 cases. J Neurooncol 1999;45:219-27
23. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 2000;177:72-82
24. Reyes-Mugica M, Chou PM, Myint MM, Ridaura-Sanz C, Gonzales-Crussi F, Tomita T. Ependymomas in children: Histologic and DNA-flow cytometric study. Pediatr Pathol 1994;14:453-66
25. Kotylo PK, Robertson PB, Fineberg NS, Azzarelli B, Jakacki R. Flow cytometric DNA analysis of pediatric intracranial ependymomas. Arch Pathol Lab Med 1997;121:1255-58
26. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002;86:929-39
27. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 2002;161:2133-41
28. Ward S, Harding B, Wilkins P, et al. Gain of 1q and loss of 22q are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma. Genes Chromosomes Cancer 2001;32:59-66
29. Qualman SJ, Shannon BT, Boesel CP, Jacobs D, Jinkens C, Hayes J, Ploidy analysis and cerebrospinal fluid nephelometry as measures of clinical outcome in childhood choroid plexus neoplasia. Pathol Annu 1992;27:305-21
30. Rickert CH, Wiestler OD, Paulus W. Chromosomal imbalances in choroid plexus tumors. Am J Pathol 2002;160:1105-13
31. Coons SW, Johnson PC, Haskett D, Rider R. Flow cytometric analysis of deoxyribonucleic acid ploidy and proliferation in choroid plexus tumors. Neurosurgery 1992;31:850-56
32. Centeno BA, Louis DN, Kupsky WJ, Preffer FI, Sobel RA. The AgNOR technique, PCNA immunohistochemistry, and DNA ploidy in the evaluation of choroid plexus biopsy specimens. Am J Clin Pathol 1993;100:690-96
33. Juros E, Lunec J, Perry RH, Kelly PJ, Pearson AD. p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer 1993;68:801-7
34. Woodburn RT, Azzarelli B, Montebello JF, Goss IE. Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 2001;52:57-62
35. Adesina AM, Dunn ST, Moore WE, Nalbantoglu J. Expression of p27kip1 and p53 in medulloblastoma: Relationship with cell proliferation and survival. Pathol Res Pract 2000;196:243-50
36. Nam DH, Wang KC, Kim YM, Chi JG, Kim SK, Cho BK. The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J Korean Med Sci 2000;15:452-56
37. Korshunov A, Golanov A, Ozerov S, Sycheva R. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol 1999;16:37-44
38. Gilbertson RJ, Pearson AD, Perry RH, Jaros E, Kelly PJ. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-77
39. Herms JW, Behnke J, Bergmann M, et al. Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 1997;19:510-15
40. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80
41. Gilbertson RJ, Clifford SC, MacMeekin W, et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma. Cancer Res 1998;58:3932-41
42. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001;85:705-12
43. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-93
44. Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L. Bcl-2 distribution in neuroepithelial tumors: An immunohistochemical study. J Neurooncol 1996;27:101-9
45. Miralbell R, Tolnay M, Bieri, S, et al. Pediatric medulloblastoma: Prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neurooncol 1999;45:103-10
46. Moriuchi S, Shimizu K, Miyao Y, Hayakawa T. An immunohistochemical analysis of medulloblastoma and PNET with emphasis on N-myc protein expression. Anticancer Res 1996;16:2687-92
47. Michiels EM, Weiss MM, Hoovers JM, et al. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol 2002;24:205-10
48. Eberhart CG, Kratz JE, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63:441-49
49. Scheurlen WG, Schwabe GC, Joos S, Möllenhauer J, Sörensen N, Kühl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998;16:2478-85
50. Schütz BR, Scheurlen W, Kraus J, et al. Mapping of chromosomal gains and losses in primitive neuroectodermal tumors by comparative genomic hybridization. Genes Chromosomes Cancer 1996;16:196-203
51. Gilhuis HJ, Anderl KL, Boerman RH, et al. Comparative genomic hybridization of medulloblastomas and clinical relevance: Eleven new cases and a review of the literature. Clin Neurol Neurosurg 2000;102:203-9
52. Herms J, Neidt I, Lüscher I, et al. C-myc expression in medulloblastoma and its prognostic value. Int J Cancer 2000;89:395-402
53. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-33
54. Korshunov A, Savostikova M, Ozerov S. Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression. J Neurooncol 2002;58:271-79
55. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-44
56. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 1994;91:12867-71
57. Kim JY, Sutton ME, Lu DJ, et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999;59:711-19
58. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027-35
59. Fan X, Wang Y, Kratz J, et al. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol 2003;162:1763-69
60. Chou PM, Reyes-Mugica M, Barquin N, Yasuda T, Tan X, Tomita T. Multidrug resistance gene expression in childhood medulloblastoma: Correlation with clinical outcome and DNA ploidy in 29 patients. Pediatr Neurosurg 1995;23:283-91
61. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52
62. Rostomily RC, Bermingharn-McDonogh O, Berger MS, Tapscott SJ, Reh TA, Olson JM. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res 1997;57:3526-31
63. Rood BR, Zhang H, Weitman DM, Cogen PH. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res 2002;62:3794-97
64. Tomita T, Yasue M, Engelhard HH, McLone DG, Gonzalez-Crussi F, Bauer KD. Flow cytometric DNA analysis of medulloblastoma. Prognostic implication of aneuploidy. Cancer 1988;61:744-49
65. Yasue M, Tomita T, Engelhard H, Gonzales-Crussi F, McLone DG, Bauer KD. Prognostic importance of DNA ploidy in medulloblastoma of childhood. J Neurosurg 1989;70:385-91
66. Tomita T, Das L, Radkowski MA. Bone metastases of medulloblastoma in childhood; Correlation with flow cytometric DNA analysis. J Neurooncol 1990;8:113-20
67. Schofield DE, Yunis EJ, Geyer JR, Albright AL, Berger MS, Taylor SR. DNA content and other prognostic features in childhood medulloblastoma. Proposal of a scoring system. Cancer 1992;69:1307-14
68. Gajjar AJ, Heideman RL, Douglass EC, et al. Relation of tumor-cell ploidy to survival in children with medulloblastoma. J Clin Oncol 1993;11:2211-17
69. Zerbini C, Gelber RD, Weinberg D, et al. Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol 1993;11:616-22
70. Tait DM, Eeles RA, Carter R, Ashley S, Ormerod MG. Ploidy and proliferative index in medulloblastoma: Useful prognostic factors? Eur J Cancer 1993;29A:1383-87
71. Cogen PH. Prognostic significance of molecular genetic markers in childhood brain tumors. Pediatr Neurosurg 1991;17:245-50
72. Batra SK, McLendon RE, Koo JS, et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995;24:39-45
73. Steichen-Gersdorf E, Baumgartner M, Kreczy A, Maier H, Fink FM. Deletion mapping on chromosome 17p in medulloblastoma. Br J Cancer 1997;76:1284-87
74. Emadian SM, McDonald JD, Gerken SC, Fults D. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res 1996;2:1559-64
75. Biegel JA, Janss AJ, Raffel C, et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res 1997;3:473-78
76. Nicholson JC, Ross FM, Kohler JA, Ellison DW. Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer 1999;80:1322-31
77. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44
78. Nishizaki T, Harada K, Kubota H, Ozaki S, Ito H, Sasaki K. Genetic alterations in pediatric medulloblastomas detected by comparative genomic hybridization. Pediatr Neurosurg 1999;31:27-32
79. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004;22:994-98
80. Marshall T, Rutledge JC. Flow cytometry DNA applications in pediatric tumor pathology. Pediatr Dev Pathol 2000;3:314-34
81. Hall PA, Going JJ. Predicting the future: A critical appraisal of cancer prognosis studies. Histopathology 1999;35:489-94